Daily non-political popular news in brief.
VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
10-25-2007 · EurekAlert!Shire plc, the global specialty biopharmaceutical company, announced that a phase 3 study demonstrated adults experienced significant improvements in ADHD symptom control within one week of treatment with once-daily VYVANSE, the first prodrug stimulant.
Read more »
Keywords: vyvanse, trial, adult, adhd, demonstrated, significant, efficacy, week, daily, treatment
« Previous | Next »
Similar news on "VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment":
- Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
05-23-2007 · EurekAlert!
Shire plc today announced that VYVANSE effectively controlled ADHD symptoms in children aged 6 to 12 years. In addition, 95 percent of children taking VYVANSE daily for 12 months showed overall improvement, according to phase 3 open-label extension trial results. Further analysis of phase 2 clinical data demonstrated that VYVANSE provided consistent time to maximum concentration of d-amphetamine from patient to patient. Both studies were presented at the annual meeting of the American Psychiatric Association.
Similar news · Read more »
- 12-month study demonstrated tolerability and efficacy of Daytrana
05-23-2007 · EurekAlert!
Shire plc announced that Daytrana, the first and only non-oral medication approved for treatment of ADHD in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association annual meeting.
Similar news · Read more »
- A new method of adult stem cell growth efficacious in treatment of disorders of the cornea
07-19-2007 · EurekAlert!
A new method of adult stem cell growth, designed in the Area of Cellular Therapy of the University Clinic (University of Navarra), has demonstrated its efficacy for its capacity to grow cornea stem cells.
Similar news · Read more »
- DAYTRANA (methylphenidate transdermal system) provides individualized ADHD symptom management
10-27-2006 · EurekAlert!
Shire's Attention Deficit Hyperactivity Disorder patch, DAYTRANA tm (methylphenidate transdermal system) has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when removed earlier than the recommended nine hours. The ability to remove the patch earlier allows physicians the opportunity to manage potential late-day side effects, such as lack of appetite or difficulty sleeping, according to phase 3b trial results reported at a scientific child and adolescent psychiatry meeting in San Diego.
Similar news · Read more »
- Data showed improved quality of life and patient satisfaction with SYMBICORT
05-22-2007 · EurekAlert!
New data demonstrated that the combination asthma therapy, SYMBICORT(budesonide/formoterol fumarate dihydrate), led to significant improvements in health-related quality of life and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol) or placebo. The results from these two 12-week randomized, double-blind trials were presented at the American Thoracic Society 2007 International Conference held in San Francisco, May 18-23.
Similar news · Read more »
- HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
11-05-2007 · EurekAlert!
This Phase 2b study demonstrated that, with half as many injections as Pegasys (peginterferon alfa 2a), Albuferon was just as effective in achieving sustained virologic response -- an undetectable amount of virus in the blood at 24 weeks following the end of treatment -- with comparable safety and less impairment of health-related quality of life on treatment. Albuferon is administered every two weeks, while peginterferon alfa-2a requires administration every week.
Similar news · Read more »
- Daytrana provides significant effectiveness in both boys and girls with ADHD
05-23-2007 · EurekAlert!
Shire plc announced that DAYTRANA, its ADHD patch medication, had significant efficacy in reducing the symptoms of ADHD in both male and female children aged 6 to 12 years, according to clinical trial results reported at the American Psychiatric Association annual meeting. Few clinical studies have examined gender differences in the response to ADHD treatments.
Similar news · Read more »
- Interferon does not slow or stop hepatitis C from worsening, study finds
11-08-2007 · EurekAlert!
Interferon does not slow or halt the progression of chronic hepatitis C and advanced liver disease in patients who haven't responded to previous attempts to eradicate the disease, a national study has found. Patients who were treated with interferon did experience a significant decrease in viral levels and liver inflammation, but the trial unequivocally demonstrated that treatment with interferon does not prevent the worsening of liver disease in patients who've failed prior treatments.
Similar news · Read more »
- First human trial tests stem-cell-based treatment for heart attacks
03-25-2007 · EurekAlert!
Previous research on the efficacy of stem cell therapy for heart repair has shown possible benefit from mesenchymal stem cells (MSCs) -- cells found in bone marrow that create connective tissue, bone and cartilage. A study presented today at the American College of Cardiology's Innovation in Intervention: i2 Summit reveals the results of the first human trial using MSCs for the treatment of myocardial infarction (MI, or heart attack).
Similar news · Read more »
- GSK announces launch of largest ever Phase III trial in lung cancer treatment
06-05-2007 · EurekAlert!
GlaxoSmithKline today announced final results of a Phase II clinical trial of its investigational Antigen-Specific Cancer Immunotherapeutic MAGE-A3 in non small cell lung cancer. Final trial analysis showed a 27 percent reduction in the relative risk of cancer recurrence following surgery, compared to placebo. GSK also announced today the launch of a Phase III efficacy and safety trial for this novel cancer immunotherapy; the largest clinical trial ever conducted in lung cancer treatment.
Similar news · Read more »
